gemcitabine + doxorubicin + cisplatin

Gemcitabine + doxorubicin + cisplatin is a three-drug combination regimen composed of: - **Gemcitabine**, a nucleoside analog that inhibits DNA synthesis by incorporation into DNA and by inhibition of ribonucleotide reductase, leading to cell cycle arrest and apoptosis - **Doxorubicin**, an anthracycline antibiotic that intercalates into DNA, inhibits topoisomerase II, and generates free radicals, causing DNA damage and disruption of replication/transcription - **Cisplatin**, a platinum-based compound that forms DNA crosslinks, disrupting DNA structure and function, resulting in apoptosis This combination is an investigational or non-standard multi-agent chemotherapy regimen, primarily composed of agents individually approved and widely used in the treatment of various solid tumors (notably bladder, breast, ovarian, and lung cancers), but the specific three-drug combination is not an established standard-of-care protocol. It is most relevant in oncology as a cytotoxic chemotherapeutic regimen for treating advanced solid tumors, particularly urothelial (bladder) cancers, and may be considered in clinical studies or experimental therapeutics.